Physician profile
Christopher E Baur
NPI 1417913591
$2,416.28
in general payments reported to CMS, 2019-2025
39 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $102 · 2021: $293 · 2022: $321 · 2023: $668 · 2024: $528 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.53 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $245.16 | 2021-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $236.46 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $176.62 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $132.37 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $127.21 | 2019-2023 | |
| Abbvie INC. | $106.21 | 2021-2023 | Vraylar |
| Xeris Pharmaceuticals, INC. | $82.10 | 2021-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.98 | 2022-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.35 | 2023-2025 | Caplyta |
| Pfizer INC. | $52.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.71 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $47.00 | 2021-2023 | |
| Exact Sciences Corporation | $46.36 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $41.58 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $41.09 | 2024-2025 | Interstim, Intellis Adaptivestim |
| Corcept Therapeutics | $40.61 | 2025 | Korlym |
| Vbi Vaccine (Delaware) INC. | $38.33 | 2022 | |
| Abbott Laboratories | $37.64 | 2019-2023 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2019-2021 | |
| Phadia US INC. | $35.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.46 | 2023-2024 | Xifaxan |
| Daiichi Sankyo INC. | $33.31 | 2022-2024 | Injectafer |
| Allergan, INC. | $31.50 | 2019 | |
| Shield Therapeutics INC | $30.80 | 2024-2025 | |
| Eisai INC. | $28.07 | 2021 | |
| Abiomed | $26.22 | 2024 | Impella |
| Amgen INC. | $25.11 | 2019-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $19.40 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $19.32 | 2023 | Gemtesa |
| Forte Bio-Pharma LLC | $18.73 | 2023 | Prolate, Nalocet |
| Merck Sharp & Dohme LLC | $18.27 | 2024 | Gardasil 9, Vaxelis, Capvaxive |
| Cvrx, INC. | $17.72 | 2023-2024 | Barostim Neo System |
| Stryker Corporation | $14.96 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $13.98 | 2021 | |
| Seqirus USA INC | $13.65 | 2025 | Flucelvax, Fluad |
| Biohaven Pharmaceuticals, INC. | $13.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.